Urovant Sciences
General Information | |
Business: |
We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our product candidate, vibegron, is an oral, once-daily, small molecule that, based on in vitro data, is a potent and highly selective beta-3 agonist. We are currently evaluating vibegron in our 1,400 patient, international pivotal Phase 3 clinical trial for the treatment of overactive bladder, or OAB. We expect to report top-line results from this clinical trial in the first or second quarter of 2019, and if the results are positive, we plan to submit a new drug application to the U.S. Food and Drug Administration, or FDA, by early 2020.
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 0 |
Founded: | 2016 |
Contact Information | |
Address | Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom |
Phone Number | +44 203 318 9709 |
Web Address | http://www.urovant.com |
View Prospectus: | Urovant Sciences |
Financial Information | |
Market Cap | $420.4mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-64.8 mil (last 12 months) |
IPO Profile | |
Symbol | UROV |
Exchange | NASDAQ |
Shares (millions): | 10.0 |
Price range | $14.00 - $14.00 |
Est. $ Volume | $140.0 mil |
Manager / Joint Managers | J.P. Morgan/ Jefferies/ Cowen |
CO-Managers | - |
Expected To Trade: | 9/27/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |